FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis

TARRYTOWN, N.Y. and PARIS , May 20, 2022 /PRNewswire/ — Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States ; approval granted more than two months ahead of FDA’s Priority Review action date Dupixent 300 mg weekly significantly improved signs